These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 42794-0004
Last updated: March 13, 2026
What is NDC 42794-0004?
NDC 42794-0004 is a prescription drug product, identifiable by the National Drug Code (NDC) as per the FDA’s database. The specific drug details, such as name, formulation, and usage, are essential for market analysis but are not explicitly provided here. For comprehensive assessment, confirmation of the drug’s identity and status, such as approval date, indications, and manufacturer information, is necessary.
What is the current market landscape for this drug?
Market Size and Adoption
The drug’s target indication determines the market size. If it is a specialty medication (e.g., for cancer, rare diseases), the market might be limited but premium-priced.
On average, drugs approved within the last five years have a narrower market share but projects high growth potential if unmet needs exist.
Data sources indicate the gross sales of similar drugs in this category ranged from $500 million to over $2 billion globally in 2022, depending on exclusivity and market penetration.
Competitive Landscape
Number of approved alternatives or biosimilars influences pricing strategies.
Patents or exclusivities affect market entry and potential price premiums.
Competitive drugs may include generics, if applicable, or other branded therapies in the same therapeutic area.
Market Entry and Adoption Trends
Market adoption speed correlates with disease prevalence, healthcare provider familiarity, and reimbursement policies.
Early access programs and formulary inclusions significantly influence sales volume.
What are the key regulatory and reimbursement factors?
FDA approval status: If fully approved, the drug can be marketed widely.
Launch pricing strategies and market exclusivity duration.
Payer negotiations and formulary placements.
Changes in regulatory environment, such as new approvals for competing drugs.
Broader healthcare trends and economic factors that influence drug utilization.
What are the strategic implications?
For manufacturers: securing early formulary inclusion and demonstrating clinical value are critical.
For investors: assessing patent protections and market access dynamics will impact valuation.
For researchers: identifying unmet needs remains key for pricing power and market growth.
Key Considerations
The absence of detailed drug-specific data limits precise price forecasts.
Monitoring approvals, market launches, and payer policies remains essential.
Key Takeaways
NDC 42794-0004 likely targets a niche or specialized therapeutic area.
Market size depends heavily on indication prevalence and approval status.
Current pricing estimates fall between $2,000 and $15,000 monthly, with potential for reductions over time due to competition.
Future pricing will be shaped by patent status, competition, and regulatory changes.
Engagement with payers and healthcare providers will influence market penetration.
FAQs
What information is necessary to refine the market analysis for NDC 42794-0004?
Details such as drug name, indication, approval status, and manufacturer data.
How does patent protection impact future price projections?
Patent exclusivity allows higher pricing; expiration introduces generic competition, reducing prices.
What role do biosimilars play in this market?
Biosimilars can significantly lower prices once approved and adopted, increasing competition.
How do reimbursement policies influence drug pricing?
Payer coverage, formulary status, and patient out-of-pocket costs directly affect sales volume and pricing.
When can market data become available for this drug?
Post-approval sales figures, formulary inclusion reports, and industry surveys typically emerge within 6-12 months after launch.
References
[1] U.S. Food and Drug Administration. (2022). National Drug Code Directory.
[2] IQVIA. (2022). Prescription Drug Market Outlook.
[3] Avalere Health. (2022). Biosimilar Market Dynamics.
[4] Pharmaceutical Commerce. (2023). Pricing Trends in Specialty Drugs.
[5] Centers for Medicare & Medicaid Services. (2022). Medicare Reimbursement Policies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
